Indivior Pharmaceuticals, Inc.
INDV
$34.59
-$0.18-0.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.46% | 10.25% | 4.29% | -0.17% | 2.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.46% | 10.25% | 4.29% | -0.17% | 2.35% |
| Cost of Revenue | -5.47% | -14.91% | -10.81% | -9.91% | -0.50% |
| Gross Profit | 17.37% | 16.33% | 7.76% | 1.96% | 2.96% |
| SG&A Expenses | -11.19% | -4.22% | -3.98% | -0.99% | -3.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 20.00% | 20.00% | 20.00% | -150.00% | 37.50% |
| Total Operating Expenses | -12.91% | -10.03% | -7.98% | -5.82% | -3.88% |
| Operating Income | 96.47% | 83.46% | 47.71% | 20.39% | 28.64% |
| Income Before Tax | 109.04% | 4,816.67% | 1,090.00% | 283.96% | 159.31% |
| Income Tax Expenses | -52.50% | 238.46% | 123.08% | 546.67% | 215.94% |
| Earnings from Continuing Operations | 228.70% | 3,685.71% | 2,885.71% | 240.66% | 143.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 228.70% | 3,685.71% | 2,885.71% | 240.66% | 143.55% |
| EBIT | 96.47% | 83.46% | 47.71% | 20.39% | 28.64% |
| EBITDA | 92.18% | 79.25% | 44.36% | 16.54% | 23.01% |
| EPS Basic | 238.81% | 29,342.03% | 2,582.11% | 258.73% | 147.72% |
| Normalized Basic EPS | 125.71% | 102.29% | 58.51% | 21.64% | 24.29% |
| EPS Diluted | 230.19% | 13,012.58% | 2,912.50% | 255.21% | 147.09% |
| Normalized Diluted EPS | 119.16% | 97.23% | 55.57% | 20.07% | 23.54% |
| Average Basic Shares Outstanding | -3.00% | -3.71% | -5.90% | -8.14% | -7.82% |
| Average Diluted Shares Outstanding | -0.19% | -1.53% | -4.50% | -7.11% | -7.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |